Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according ...

Using real-world data from over 300,000 cases, scientists uncovered a significant link between semaglutide and reported vision problems—raising new concerns about the safety profile of this ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar ...

However, at the two-year, three-year, and four-year time points from the index date, those taking semaglutide had an increased risk for NAION (hazard ratios, 2.39, 2.44, and 2.05, respectively).

Semaglutide use associated with increased risk for NAION at the two-, three-, and four-year time point from the index date. (HealthDay News) — For patients with diabetes, semaglutide use is ...

The researchers found that based on 551 cases, there were an estimated 24,499 emergency department visits attributed to semaglutide adverse events in 2022 through 2023 (mean patient age, 50.9 ...

The large-scale study focused on use of semaglutide and non-GLP-1 RAs. An increased risk for nonarteritic anterior ischemic optic neuropathy with semaglutide was seen at 2, 3 and 4 years from the ...

Most common gastrointestinal issues seen were nausea/vomiting, abdominal pain, and diarrhea. HealthDay News — The rate of emergency department visits for adverse events among patients dispensed ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar ...

Semaglutide, the medication better known as Ozempic, reduces the symptoms of a condition that can lead to lower limb amputations in people with diabetes, according to a new study that reinforces ...

Tennis. Serena Williams' husband, Alexis Ohanian, puts aside his best skills to create another happy moment with Olympia Tennis. Serena Williams 'flees' daughter Olympia for a much-needed ...

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...